RHHBY Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of -- compared to Roche Holding AG's net margin of 31.72%. Roche Holding AG's return on equity of 28.65% beat Eli Lilly & Co.'s return on equity of 106.26%.

Roche Holding AG has a consensus price target of $51.13, signalling upside risk potential of 4.52%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,045.59 which suggests that it could grow by 1.16%. Given that Roche Holding AG has higher upside potential than Eli Lilly & Co., analysts believe Roche Holding AG is more attractive than Eli Lilly & Co..

Roche Holding AG has a beta of 0.460, which suggesting that the stock is 53.97% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 2.84%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Roche Holding AG pays 58.07% of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Roche Holding AG's net income of -- is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Roche Holding AG's price-to-earnings ratio is 28.80x while Eli Lilly & Co.'s PE ratio is 51.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.42x versus 15.86x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -- compared to Roche Holding AG's net margin of 33.68%. Roche Holding AG's return on equity of 28.65% beat Merck & Co., Inc.'s return on equity of 39.63%.

Roche Holding AG has a consensus price target of $51.13, signalling upside risk potential of 4.52%. On the other hand Merck & Co., Inc. has an analysts' consensus of $105.35 which suggests that it could grow by 3.01%. Given that Roche Holding AG has higher upside potential than Merck & Co., Inc., analysts believe Roche Holding AG is more attractive than Merck & Co., Inc..

Roche Holding AG has a beta of 0.460, which suggesting that the stock is 53.97% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 2.84%. Merck & Co., Inc. offers a yield of 3.17% to investors and pays a quarterly dividend of $0.81 per share. Roche Holding AG pays 58.07% of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Roche Holding AG's net income of -- is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Roche Holding AG's price-to-earnings ratio is 28.80x while Merck & Co., Inc.'s PE ratio is 13.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.42x versus 4.03x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -- compared to Roche Holding AG's net margin of 28.26%. Roche Holding AG's return on equity of 28.65% beat Novartis AG's return on equity of 33.87%.

Roche Holding AG has a consensus price target of $51.13, signalling upside risk potential of 4.52%. On the other hand Novartis AG has an analysts' consensus of $134.88 which suggests that it could grow by 0.87%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Roche Holding AG has a beta of 0.460, which suggesting that the stock is 53.97% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.542%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 2.84%. Novartis AG offers a yield of 2.99% to investors and pays a quarterly dividend of $3.99 per share. Roche Holding AG pays 58.07% of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.9B. Roche Holding AG's net income of -- is lower than Novartis AG's net income of $3.9B. Notably, Roche Holding AG's price-to-earnings ratio is 28.80x while Novartis AG's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.42x versus 4.84x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Roche Holding AG's net margin of 21.32%. Roche Holding AG's return on equity of 28.65% beat Pfizer Inc.'s return on equity of 10.84%.

Roche Holding AG has a consensus price target of $51.13, signalling upside risk potential of 4.52%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Pfizer Inc. has higher upside potential than Roche Holding AG, analysts believe Pfizer Inc. is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.460, which suggesting that the stock is 53.97% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 2.84%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Roche Holding AG pays 58.07% of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.

Roche Holding AG quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Roche Holding AG's net income of -- is lower than Pfizer Inc.'s net income of $3.6B. Notably, Roche Holding AG's price-to-earnings ratio is 28.80x while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.42x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.